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Abstract
Hundreds of genes are implicated in autism spectrum disorder (ASD) but the mechanisms through 
which they contribute to ASD pathophysiology remain elusive. Here, we analyzed leukocyte 
transcriptomics from 1–4 year-old male toddlers with ASD or typical development from the 
general population. We discovered a perturbed gene network that includes genes that are highly 
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expressed during fetal brain development and which is dysregulated in hiPSC-derived neuron 
models of ASD. High-confidence ASD risk genes emerge as upstream regulators of the network, 
and many risk genes may impact the network by modulating RAS/ERK, PI3K/AKT, and WNT/β-
catenin signaling pathways. We found that the degree of dysregulation in this network correlated 
with the severity of ASD symptoms in the toddlers. These results demonstrate how the 
heterogeneous genetics of ASD may dysregulate a core network to influence brain development at 
prenatal and very early postnatal ages and, thereby, the severity of later ASD symptoms.
INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with prenatal and early 
postnatal biological onset1–3. Genetic factors contribute to the predisposition and 
development of ASD with estimated heritability rates of 50–83%4,5. Large genetic studies 
have implicated several hundred ASD risk (rASD) genes that could be associated with many 
different pathways, cellular processes, and neurodevelopmental stages6–10. This highly 
heterogeneous genetic landscape has raised challenges in elucidating the biological 
mechanisms involved in the disorder. While rigorous proof remains lacking, current 
evidence suggests that rASD genes fall into networks and biological processes6,7,9,11 that 
modulate one or more stages of prenatal and early postnatal brain development, including 
neuron proliferation, migration, neurite growth, and synapse formation or function3,8. 
However, these insights are mostly gained from studies focused on single rASD genes3 or 
transcriptome analyses of neurotypical brains9,11. Thus, we have an incomplete picture of 
the molecular changes at the individual level and their role in the observed heterogeneity in 
the core clinical deficits of socialization and restricted, repetitive behavior.
To further complicate efforts, rASD genes have been largely identified through de novo loss-
of-function mutations in their coding sequence. Such events contribute to ASD risk in 5–
10% of the ASD population, and most of heritable genetic risk is thought to reside in 
common variants that are also found in subjects with typical development5,12–15. It remains 
unclear whether ASD in subjects with known rASD gene mutations manifests as ASD 
subtypes with distinct molecular etiologies, or whether the underlying mechanisms are 
shared with the overall population of subjects with ASD.
To address these questions, it is important to understand which molecular processes are 
perturbed in prenatal and early postnatal life in individuals with ASD, assess how they vary 
among subjects, and evaluate how these perturbations relate to rASD genes and early-age 
clinical ASD symptoms. It is expected that the genetic changes in ASD alter gene expression 
and signaling in the developing brain3,7,10. Therefore, capturing dysregulated gene 
expression at prenatal and early postnatal ages may unravel the molecular organization 
underlying ASD. Unfortunately, doing so is challenging as ASD cannot be clinically 
diagnosed at these early stages based on currently established behavioral symptoms16, and 
accessible postmortem brain tissues are from much older individuals with ASD, well beyond 
the ages when rASD genes are at peak expression and long after ASD diagnosis. In contrast 
to living neurons, which have a limited time window for proliferation and maturation, other 
cell types constantly regenerate, such as blood cells. Given the strong genetic basis of ASD, 
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some dysregulated developmental signals may continually reoccur in blood cells and thus be 
studied postnatally17–20.
Reinforcing this notion, it was recently demonstrated that genes that are broadly expressed 
across many tissues are major contributors to the overall heritability of complex traits, and it 
was postulated that this could be relevant to ASD21. Lending credence to this, previous 
studies have reported that differentially expressed genes in the blood of subjects with ASD 
are enriched for regulatory targets of CHD818 and FMR122, two well-known rASD genes. 
Similarly, both lymphoblastoid cells of subjects with ASD and hiPSC-derived models of 
fragile-X syndrome show over-expression of mir-181 with a potential role in the disorder23. 
Likewise, leukocytes from toddlers with ASD show perturbations in biological processes 
such as cell proliferation, differentiation, and microtubules24–27, and these coincide with 
dysregulated processes seen in hiPSC-derived neural progenitors and neurons from 
individuals with ASD and brain enlargement28,29. Ultimately, establishing the signatures of 
ASD in other tissues will facilitate the study of the molecular basis of the disorder in the first 
few years of life.
Here we leverage transcriptomic data from leukocytes, hiPSC-derived neuron models, and 
the neurotypical brain to study the architecture of transcriptional dysregulation in ASD, its 
connection to rASD genes, and its association with prenatal brain development and postnatal 
socialization symptom severity in ASD. We discovered a conserved dysregulated gene 
network by analyzing leukocyte transcriptomic data from 1–4 year-old toddlers with ASD 
and typical development (TD). The dysregulated network is enriched for pathways known to 
be perturbed in ASD neurons, involves genes that are highly expressed in prenatal brain, and 
is dysregulated in hiPSC-derived neurons from subjects with ASD and brain enlargement. 
Consistent with the postulated structure of complex traits21,30, we show that rASD genes in 
diverse functional groups converge upon and regulate this core network. Importantly, we 
found the dysregulation extent of this core network is correlated with the severity of 
socialization deficits in toddlers with ASD. Thus, our results demonstrate how the 
heterogeneous rASD genes converge and regulate a biologically relevant core network, 
capturing the possible molecular basis of ASD.
RESULTS
Increased transcriptional activity in leukocytes from toddlers with ASD
We analyzed leukocyte gene expression profiles obtained from 226 male toddlers (119 ASD 
and 107 TD, Table S1). Robust linear regression modeling of the data identified 1236 
differentially expressed (DE) genes (437 downregulated and 799 upregulated; FDR <0.05; 
Table S2). Jack-knife resampling demonstrated that the expression pattern of DE genes was 
not driven by a small number of cases, but rather shared between the vast majority of 
subjects with ASD (Fig. S1). We further validated the expression patterns in additional 
replicate and independent cohorts (Fig. S1–S4; Table S1).
In many disease conditions, transcriptional programs in cells deviate from normal states due 
to dysregulations in signaling pathways, transcription factors and epigenetic marks. 
Therefore, we employed a systems approach to decipher network-level transcriptional 
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perturbations in leukocytes of toddlers with ASD (Fig. 1). We reasoned that perturbations to 
ASD-associated molecular pathways would be reflected in the co-expression patterns 
between DE genes. To identify such ASD-relevant dysregulations, we first extracted a static 
gene network (that is, the network is indifferent to the cell context) composed of all known 
high-confidence physical and regulatory interactions among the DE genes (Methods). We 
next pruned the static network using our leukocyte transcriptome data to obtain context-
specific networks of each diagnosis group separately (that is, the networks differ in genes 
and their interactions, based on their associated gene expression data). Specifically, context-
specific networks were built for each of ASD and TD groups by only retaining those 
interactions from the static network that were significantly co-expressed (FDR <0.05) within 
the group (Table S3). Both context-specific networks, called DE-ASD and DE-TD, were 
constructed based on the same static network from the same set of genes (i.e., genes that are 
expressed in leukocytes and show differential expression). However, following removal of 
interactions lacking co-expression, a proportion of genes become unconnected and these 
were consequently removed from the DE-ASD and DE-TD networks. Therefore, DE-ASD 
and DE-TD exhibited 63% overlap in their gene composition, with differences mostly 
related to genes that were loosely connected in the starting static network. To ensure the 
robustness of our conclusions to the changes in the structure of the static network, we 
replicated all presented results on two other static networks with higher density of 
interactions that resulted in a higher number of overlapping genes between corresponding 
context-specific networks (Methods).
To test if transcriptional programs were being modulated in ASD, we merged the genes and 
interactions in the DE-ASD and DE-TD networks, and compared the ‘co-expression 
magnitude’ of interactions in the merged network between ASD and TD samples31–33. This 
proxy for the transcriptional activity of gene networks9 demonstrated that co-expression 
magnitude was higher in the ASD than the TD samples (Fig. 2a; p-value <0.01; paired 
Wilcoxon-Mann-Whitney test). The stronger co-expression in the DE-ASD network 
suggests a higher level of concerted activation or suppression of pathways involving DE 
genes among the subjects with ASD. Further analysis confirmed that the changes in the co-
expression magnitude, rather than the gene composition, is the primary driver of the elevated 
network transcriptional activity (Table S4). This higher level of concerted co-regulation of 
the network was also reproducible in two additional ASD transcriptomic datasets and across 
alternative analysis methods (Fig. S1–S4).
In summary, the leukocyte transcriptional networks of the DE genes show higher than 
normal co-expression activity in ASD. Moreover, the dysregulation pattern is present in a 
large percentage of toddlers with ASD, as evidenced by the resampling analyses and the 
other two ASD datasets.
The leukocyte-based gene network captures transcriptional programs associated with 
brain development
We next assessed the potential involvement of the leukocyte-based network to gene 
expression patterns during brain development. By overlaying the neurodevelopmental RNA-
Seq data from BrainSpan34,35 on our DE-ASD network, we found that the DE-ASD network 
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was enriched for highly expressed genes in the neocortex at prenatal and early postnatal 
periods (p-value <4.3×10−30; Fig. 2b).
To investigate the spatiotemporal activity of the DE-ASD network during brain 
development, we measured the magnitude of gene co-expression within the DE-ASD 
network at different neurodevelopmental time windows across brain regions. We found that 
the highest levels of co-expression of the DE-ASD network temporally coincided with peak 
neural proliferation in brain development (10–19 post conception weeks3,8), after which co-
expression activity gradually decreased (Fig. 2c; Fig. S5). Expression levels of genes in the 
DE-ASD network followed a similar pattern (Fig. S6). Further supporting the transcriptional 
activity of the leukocyte-derived DE-ASD network in prenatal brain, we found evidence that 
the network is mostly preserved at the co-expression level between ASD leukocytes and 
prenatal brain. Specifically, the direction of correlations (i.e., positive or negative) in the 
leukocyte transcriptome of subjects with ASD is mostly preserved in prenatal and early 
postnatal brain (Fig. 2d). Importantly, this preservation of co-expression was significantly 
higher in the DE-ASD network than in the DE-TD network (p-value <10−16; Fig. S6).
rASD genes are associated with the DE-ASD network
We next analyzed the DE-ASD network in the context of other studies to test the relevance 
of our DE-ASD network to ASD. Parikshak et al. previously reported gene co-expression 
modules associated with cortical laminae development during prenatal and early postnatal 
ages11. A subset of these modules show enrichment in rASD genes11. We examined the 
overlap of our leukocyte-derived network with all modules from Parikshak et al11. The DE-
ASD network preferentially overlapped with rASD gene-enriched modules from that study 
(Fig. 2e; Table S5). This suggests that our DE-ASD network is functionally related to rASD 
genes during neocortical development. Our DE-ASD network also overlapped with the 
networks of rASD genes reported in other studies7,9, indicating the robustness of the results 
(Fig. 2e). Intriguingly, the prenatal brain co-expression network of high-confidence rASD 
genes was more similar to that of ASD leukocytes than TD leukocytes (Fig. 2f), suggesting 
that neurodevelopmental transcriptional programs related to rASD genes might be more 
active in the leukocyte transcriptome of toddlers with ASD than in that of TD toddlers.
With the observed overlap patterns, we next tested for enrichment of rASD genes in the DE-
ASD network. For this analysis, we considered different rASD gene lists of different size 
and varying confidence levels (Methods). Surprisingly, this analysis demonstrated that rASD 
genes are not enriched in the DE-ASD network (p-value >0.19).
The DE-ASD network is enriched for regulatory targets of rASD genes
Many high confidence rASD genes have regulatory functions3,7,10. Although the perturbed 
DE-ASD network is not enriched for rASD genes, it overlaps with brain co-expression 
modules and networks containing known rASD genes. At the mechanistic level, the 
observed co-expression of rASD and DE genes in the prenatal brain could be due to the 
regulatory influence of rASD genes on the DE-ASD network, and thereby genetic alterations 
in rASD genes could cause the transcriptional perturbation and the increase in gene co-
expression within the DE-ASD network.
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To elucidate if rASD genes could regulate the DE-ASD network, we examined if the 
regulatory targets of rASD genes are enriched in the DE-ASD network. Indeed, we observed 
that the DE-ASD network is enriched for genes regulated by two high-confidence rASD 
genes, CHD836–38 and FMR139 (Fig. 3a). To more systematically identify regulators of the 
network, we evaluated the overlap of the DE-ASD network with the regulatory targets of 
rASD transcription factors from the ENCODE project40 and Chea2016 resource41. 
Strikingly, the DE-ASD network is significantly enriched for the regulatory targets of 11 out 
of 20 high-confidence, strong-candidate and suggestive-evidence rASD genes (SFARI 
categories 1–3) (OR: 2.54; p-value: 0.05; Fig. 3b; Table S6).
The DE-ASD network is preferentially linked to high-confidence rASD genes
rASD genes were often not differentially expressed in ASD leukocytes, and the DE-ASD 
network was therefore not enriched in rASD genes. To explore if rASD genes may 
nevertheless regulate the DE-ASD network, we expanded the DE-ASD network by including 
rASD genes. Thus, we obtained an expanded-ASD (XP-ASD) network. To construct the XP-
ASD network, we used a similar approach to that used for the DE-ASD network. Briefly, we 
built a high-confidence static network of DE and 965 candidate rASD genes (Table S7). The 
context-specific XP-ASD network was next inferred by retaining only the significantly co-
expressed interacting pairs in ASD samples. This pruning step removed genes from the static 
network that were not significantly co-expressed with their known physically interacting 
partners or regulatory targets in ASD leukocytes. Accordingly, the XP-ASD network 
included a total of 316 out of 965 (36%) likely rASD genes (Table S3).
The 965 rASD genes included both high-confidence rASD genes (e.g., recurrently mutated 
in individuals with ASD) and low-confidence rASD genes (some even found in siblings of 
individuals with ASD, who developed normally). We reasoned that if the XP-ASD network 
is truly relevant to the prenatal etiology of ASD, high-confidence rASD genes would be 
preferentially incorporated into the XP-ASD network. By following different analytical 
methods, other researchers have independently categorized rASD genes into high- and low-
confidence7,14,42. Importantly, we found a reproducible enrichment of high-confidence 
rASD genes in the XP-ASD network (Fig. 3c). We also observed a significant enrichment 
for strong-candidate rASD genes with de novo protein truncating variants in the XP-ASD 
network (hypergeometric p-value <3.6×10−6). Further corroborating a possible regulatory 
role of rASD genes on the DE-ASD network, rASD genes in the XP-ASD network were 
significantly enriched for DNA-binding activity, compared to the remaining rASD genes 
(OR: 3.1; p-value <2.1×10−12; Fisher’s exact test; Fig. S7). Furthermore, the XP-ASD 
network was not enriched for rASD genes classified as low-confidence (p-value >0.24; 
SFARI categories 4–6). As negative controls, we constructed two other networks by 
including genes with likely deleterious and synonymous mutations in siblings of individuals 
with ASD, who developed normally13. Consistent with a possible role of the XP-ASD 
network in ASD, these negative control genes were not significantly associated with the DE 
genes (p-values >0.41; Fig. 3c). The preferential addition of high-confidence and regulatory 
rASD genes supports the relevance of the XP-ASD network for the pathobiology of ASD, 
and the likelihood that the high-confidence rASD genes are regulating the DE-ASD network.
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rASD genes tend to be repressors of genes in the DE-ASD network
To explore how rASD genes may regulate DE genes, we analyzed their interaction types 
(i.e., positive or negative correlations, alluding to activator or repressor activity). 
Comparative analysis of interactions between DE and rASD genes in the XP-ASD network 
indicated a significant enrichment of negative correlations between rASD and DE genes 
(OR: 1.79; p-value <3.1×10−4; Fisher’s exact test), suggesting a predominantly inhibitory 
role of rASD genes on the DE genes (Fig. 4a).
In line with a role of rASD genes as repressors, the DE-ASD network was enriched for 
genes that were up-regulated by the knock-down of CHD8 in neural progenitor and stem 
cells, but not for genes that were down-regulated36–38 (Fig. 4b). Consistent with this, gene 
set enrichment analysis demonstrated an overall up-regulation of genes that are also up-
regulated in knock-down experiments of the transcriptional repressor CHD8 (p-value <0.039 
across three different studies36–38), but not for those that are down-regulated. There was a 
similar trend towards up-regulation for the binding targets of the FMR1 rASD gene in the 
ASD transcriptome39 (p-value: 0.078; GSEA).
To further test if rASD genes were predominantly repressors of genes in the DE-ASD 
network, we analyzed an independent transcriptome dataset from the differentiation of 
primary human neural progenitor cells obtained from fetal brains of three donors43. We 
found that expression of genes in the DE-ASD network exhibit a gradual down-regulation 
during neural progenitor differentiation (p-value 4.4×10−6; Fig. 4c). However, the genes 
unique to the XP-ASD network (i.e., rASD genes present in the XP-ASD network, but not 
DE-ASD network) showed an anti-correlated expression pattern with DE-ASD genes with 
peak expression at 12 weeks into differentiation (p-value 1.2×10−3; Fig. 4c). The results of 
this independent dataset provide further evidence of a potential inhibitory role of rASD 
genes on DE-ASD networks during human neuron differentiation.
Signaling pathways are central to the leukocyte-based networks
We next identified key pathways involved in the XP-ASD and DE-ASD networks. 
Biological process enrichment analysis of the XP-ASD network demonstrated it is highly 
enriched for signaling pathways (Fig. 5a; Table S8). Moreover, the DE-ASD network was 
highly enriched for PI3K/AKT, mTOR, and related pathways (Fig. 5b). To delineate 
mechanisms by which rASD genes could dysregulate DE genes, we compared enriched 
biological processes between DE and rASD genes in the XP-ASD network. DE genes were 
more enriched for cell proliferation-related processes, particularly PI3K/AKT and its 
downstream pathways such as mTOR, autophagy, viral translation, and FC receptor 
signaling (Fig. 5a–b). However, the rASD genes were more enriched for processes involved 
in neuron differentiation and maturation, including neurogenesis, dendrite development and 
synapse assembly (Fig. 5a).
Our results suggest elevated co-expression activity of PI3K/AKT and its downstream 
pathways in ASD leukocytes (Fig. 5a–b). These processes are involved in brain development 
and growth during prenatal and early postnatal ages3,45,46 and focused studies on rASD 
genes have implicated them in ASD3,10,44–46. Further supporting the increased co-
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expression activity of the PI3K/AKT and its downstream pathways in our cohort of toddlers 
with ASD, gene set enrichment analysis demonstrated that the PI3K/AKT pathway and two 
of its main downstream processes (upregulation of mTOR pathway and upregulation of 
genes that are regulated by FOXO1) are also dysregulated in ASD leukocytes in directions 
that are consistent with the increased activity of the PI3K/AKT pathway (Table S9).
We further investigated the DE-ASD and XP-ASD networks using an integrated hub 
analysis approach (Methods). In the DE-ASD network, hub genes included the key members 
of the PI3K/AKT pathway including PIK3CD, AKT1 and GSK3B (Fig. 5c; Fig. S8). Genes 
that were only hubs in the XP-ASD network included regulators of neuronal proliferation 
and maturation, including regulatory members of the RAS/ERK (e.g., NRAS, ERK2, ERK1, 
SHC1), PI3K/AKT (e.g., PTEN, PIK3R1, EP300), and WNT/β-catenin (e.g., CTNNB1, 
SMARCC2, CSNK1G2) signaling pathways (Fig. 5c; Fig. S9; Table S10–S11). While 
PI3K/AKT (a hub in DE-ASD and XP-ASD networks) promotes proliferation and survival, 
many of the genes that are only hub in the XP-ASD network, including NRAS, ERK 1/2, 
and PTEN, can trigger differentiation of neural progenitor cells by mediating PI3K/AKT and 
its downstream pathways3,44.
rASD genes regulate DE-ASD genes through specific signaling pathways
We further explored if perturbation to the rASD genes lead to the perturbation of the DE-
ASD network through changes in the RAS/ERK, PI3K/AKT, and WNT/β-catenin pathways. 
The activity of these three pathways is chiefly mediated through changes in phosphorylation 
of ERK, AKT, and β-catenin proteins. Therefore, to assess the regulatory influence of rASD 
genes on these signaling pathways, we leveraged available genome-wide mutational 
screening data wherein gene mutations were scored based on their effects on the 
phosphorylation state of ERK, AKT, and β-catenin proteins47. Consistent with the functional 
enrichment and hub analysis results, rASD genes in the XP-ASD network were significantly 
enriched for regulators of the RAS/ERK, PI3K/AKT, and WNT/β-catenin pathways (Fig. 
5d; p-value <1.9×10−10). Specifically, regulators of these pathways (FDR <0.1) accounted 
for inclusion of 39% of rASD genes in the XP-ASD network. No significant enrichment for 
regulators of the RAS/ERK, PI3K/AKT, and WNT/β-catenin pathways was observed among 
rASD genes that were not included in the XP-ASD network (Fig. 5d). These results support 
the notion that rASD genes regulate the DE-ASD network through perturbation of the RAS/
ERK, PI3K/AKT, and WNT/β-catenin pathways.
In summary, our XP-ASD network decomposition results suggest a modular regulatory 
structure for the XP-ASD network in which diverse rASD genes converge upon and 
dysregulate activity of the DE genes (Fig. 5a). Importantly, for a large percentage of rASD 
genes, the dysregulation flow to the DE genes is channeled through highly inter-connected 
signaling pathways including RAS/ERK, PI3K/AKT, and WNT/β-catenin.
The DE-ASD network is over-active in neuron models of individuals with ASD and brain 
enlargement
Our results demonstrate increased gene co-expression in the DE-ASD network in leukocytes 
of toddlers with ASD selected from the general population. Furthermore, they implicate the 
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DE-ASD network in the prenatal etiology of ASD by demonstrating its higher co-expression 
during fetal brain development, and its connection with high-confidence rASD genes. Also, 
our results suggest that the increased co-expression in the network is present in a large 
percentage of our ASD toddlers and is associated with the processes related to the neural 
proliferation and maturation.
To further validate these results, we examined if the DE-ASD network shows increased co-
expression in hiPSC-derived neural progenitors and neurons from toddlers with ASD. Thus, 
we re-analyzed a previously published hiPSCs transcriptome data from 13 individuals with 
ASD and TD28,48, which were differentiated into neural progenitor and neuron stages. The 
included subjects with ASD capture macrocephaly which is an important phenotype 
common in many subjects with ASD. Importantly, our analysis demonstrated that the DE-
ASD network is more active in these neuron models of subjects with ASD (Fig. 6; Fig. S10). 
This result suggests the functional relevance of identified leukocyte molecular signatures to 
the abnormal brain development in ASD, particularly for individuals with brain enlargement.
Network dysregulation is associated with ASD severity
We evaluated the potential role of the DE-ASD network activity on the development of the 
core clinical symptom of socialization deficits in toddlers with ASD. To this end, we first 
tested if the same pattern of gene co-expression dysregulation exists across individuals at 
different levels of ASD severity as measured by Autism Diagnostic Observation Schedule 
(ADOS) social affect severity score. We observed that the fold change patterns of DE genes 
are almost identical across different ASD severity levels (Fig. S11). The implicated RAS/
ERK, PI3K/AKT, WNT/β-catenin pathways in our model are well known to have pleotropic 
roles during brain development, from neural proliferation and neurogenesis to neural 
migration and maturation. These signaling pathways and the associated developmental 
stages have been implicated in ASD3, suggesting the DE-ASD network is involved in 
various neurodevelopmental processes. At the mechanistic level, this suggests that the 
spectrum of autism could reflect the varying extent of dysregulation of the DE-ASD 
network, as it is composed of high-confidence physical and regulatory interactions. Hence, 
we examined whether the magnitude of the co-expression activity of the DE-ASD network 
correlated with clinical severity in toddlers with ASD. Indeed, we found that the extent of 
gene co-expression activity within the DE-ASD network was correlated with ADOS social 
affect deficit scores of toddlers with ASD (Fig. 7). To assess the significance of observed 
correlation patterns, we repeated the analysis with 10,000 permutations of the ADOS social 
affect scores in individuals with ASD. This analysis confirmed the significance of the 
observed correlations (inset boxplots in Fig. 7). Our results suggest the perturbation of the 
same network at different extents can potentially result in a spectrum of postnatal clinical 
severity levels in toddlers with ASD.
Discussion
While ASD has a strong genetic basis, it remains elusive how rASD genes are connected to 
the molecular changes underlying the disorder at prenatal and early postnatal ages. We 
developed a systems-biology framework to identify perturbed transcriptional programs in 
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leukocytes, and connect them with the rASD genes and early-age symptom severity. 
Specifically, we found a dysregulated gene network that shows elevated gene co-expression 
activity in leukocytes from toddlers with ASD. This core network was robustly associated 
with high-confidence rASD genes. Although recurrent, high confidence rASD gene 
mutations occur in a small percentage of the ASD population5,14. The connection of the DE-
ASD network (constructed with data from the general ASD pediatric population) with high-
confidence rASD genes provides evidence of shared mechanisms underlying ASD in both 
individuals with highly penetrant rASD gene mutations and those with other etiologies (e.g., 
common variants). We further show that many rASD genes may regulate the DE-ASD core 
network through the RAS/ERK, PI3K/AKT, and WNT/β-catenin signaling pathways. This 
study confirms and substantially expands results from previous reports on blood 
transcriptome of subjects with ASD (Table S12).
A key aspect of our signature is that it allows one to investigate the relationship of molecular 
perturbations with early-age ASD symptom severity. Indeed, we found that the magnitude of 
dysregulation of the DE-ASD network is correlated with deficits in ADOS social affect 
scores in male toddlers of 1–4 years old. Social and behavioral deficits are also suggested to 
be linked with the genetic variations in subjects with ASD49,50; and previous studies have 
established the effect of the PI3K/AKT signaling pathway (central to the DE-ASD core 
network) on social behaviors in mouse models45,46. Together, these observations suggest 
that the etiology of ASD converges on gene networks that correlate with ASD symptom 
severity. Moreover, our results reinforce the hypothesis that stronger dysregulation of this 
core network could lead to a higher ASD severity. The DE-ASD core network is enriched for 
pathways implicated in ASD, strongly associated with high-confidence rASD genes, and 
correlate with the ASD symptom severity. However, a direct causal relationship between the 
co-expression activity of the network and ASD remains to be established. Moreover, our co-
expression activity measure is a summary score from the strongest signal in our dataset (i.e., 
differentially expressed genes) at a group level (i.e., severity level). Therefore, by design, it 
may not comprehensively capture the heterogeneity that could exist within ASD. Future 
work is needed to explore the causal relationship of the pathways in the DE-ASD network to 
ASD development, symptoms, and the potential existence of other dysregulation 
mechanisms in individuals with ASD.
Emerging models of complex traits suggest that gene mutations and epigenetic changes 
often propagate their effects through regulatory networks and converge on core pathways 
relevant to the trait21,30. Our findings support the existence of an analogous architecture for 
ASD, wherein rASD genes with diverse biological roles converge and regulate core 
downstream pathways. Although the DE-ASD network did not significantly overlap with 
rASD genes, we found that it was significantly co-expressed with rASD genes in both 
leukocyte and brain. We also showed that the DE-ASD network genes are regulated by many 
rASD genes through direct transcriptional regulation or by modulating highly interconnected 
signaling pathways. We postulate that the DE-ASD network is a primary convergence point 
of ASD etiologies. This predicts that the spectrum of autism in such cases reflects degree 
and mechanism of the perturbation of the DE-ASD network. A detailed analysis of hiPSC-
derived neurons from subjects with ASD and brain enlargement demonstrated the 
dysregulation of the DE-ASD network in these neuron models of ASD. Furthermore, clinical 
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relevance is demonstrated by the high correlation we found between magnitude of 
dysregulation in the DE-ASD core network and ASD symptom severity in the toddlers.
The vast majority of rASD genes are not fully penetrant to the disorder3,8,14. Our analysis of 
the XP-ASD network sheds light on how rASD genes could potentially combine to result in 
ASD. Although some rASD genes could directly modulate the DE-ASD network at the 
transcriptional level, our results suggest that the regulatory consequence of many rASD 
genes on the DE-ASD network are channeled through the PI3K/AKT, RAS/ERK, WNT/β-
catenin signaling pathways. The structural and functional interrogation of the XP-ASD 
network localized these pathways to its epicenter and demonstrated enrichment for processes 
downstream of these pathways among DE genes. Moreover, we found that high-confidence 
rASD genes are better connected to the DE-ASD core network, suggesting that the closeness 
and influence of genes on these signaling pathways is correlated with their effect size on the 
disorder. These results articulate that perturbation of the PI3K/AKT, RAS/ERK, WNT/β-
catenin signaling pathways through gene regulatory networks may be an important 
etiological route for ASD that could be associated with the disorder severity level in a large 
fraction of the ASD population. Congruent with this hypothesis, cellular and animal models 
of ASD have demonstrated that high-confidence rASD genes are enriched in regulators of 
the RAS/ERK, PI3K/AKT, WNT/β-catenin signaling pathways3,10. These signaling 
pathways are highly conserved and pleiotropic, impacting multiple prenatal and early 
postnatal neural development stages from proliferation/differentiation to synaptic and neural 
circuit development3. Such multi-functionalities could be the reason that we detected the 
signal in leukocytes of individuals with ASD.
It is necessary to analyze large subject cohorts from unbiased, general pediatric community 
settings to capture the heterogeneity that underlies ASD at early ages. This study presents 
the largest transcriptome analysis thus far from such settings. However, the analyzed dataset 
is still of a modest size, and as such our analysis focused on the strongest signal that best 
differentiates ASD and TD diagnosis groups (i.e., differentially expressed genes). Here we 
illustrate that the captured signal is informative about the transcriptional organization 
underlying ASD and shows promise in bridging the gap between genetic and clinical 
outcomes. Future studies with larger datasets are required to not only replicate these results, 
but also explore other long-standing questions in the field, such as the basis of sex bias that 
exists in ASD or the potential molecular mechanisms that differentiate high-functioning 
from low-functioning individuals.
Finally, current ASD diagnostics rely solely on behavioral phenotypes of toddlers, and such 
approaches are limited by age wherein ASD can be reliably diagnosed3,16. Hence, an 
exciting direction is to expand the presented framework to systematically diagnose, classify 
and prognostically stratify subjects with ASD at earlier postnatal ages based on mRNA or 
other molecular markers. The concept of precision molecular medicine for ASD can only be 
actualized via approaches that illuminate the early-age molecular basis of ASD3,19. 
Emerging evidence represent ASD as a progressive disorder that, at prenatal and early 
postnatal stages, involves a cascade of diverse varying molecular and cellular changes, such 
as those resulting from dysregulation of the pathways and networks described in this 
paper3,28,29. As such, it will be invaluable to develop molecular assays to assess infants and 
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toddlers. The framework presented here could facilitate the development of such measures 
for ASD diagnosis and prognosis, by identifying specific molecular dysregulations that we 
show are observable in leukocytes of a large fraction of toddlers with ASD.
Materials and Methods
Participant recruitment and clinical evaluation
In this study, we performed transcriptomics analysis of 302 male toddlers with the age range 
of 1 to 4 years. The samples were divided into primary discovery and replication datasets, 
and were assayed by either microarray or RNA-Seq platforms. This included previously 
published transcriptome data (153 individuals)19 and new samples were collected using a 
similar methodology for participant recruitment (149 new cases). Research procedures were 
approved by the Institutional Review Board of the University of California, San Diego. 
Parents of subjects underwent Informed Consent Procedures with a psychologist or study 
coordinator at the time of their child’s enrollment.
About 70% of toddlers were recruited from the general population as young as 12 months 
using an early detection strategy called the 1-Year Well-Baby Check-Up Approach51. Using 
this approach, toddlers who failed a broadband screen, the CSBS IT Checklist52, at well-
baby visits in the general pediatric community settings were referred to our Center for a 
comprehensive evaluation. The remaining subjects were obtained by general community 
referrals. All toddlers received a battery of standardized psychometric tests by highly 
experienced Ph.D. level psychologists including the Autism Diagnostic Observation 
Schedule (ADOS; Module T, 1 or 2), the Mullen Scales of Early Learning and the Vineland 
Adaptive Behavior Scales. Testing sessions routinely lasted 4 hours and occurred across 2 
separate days. Toddlers younger than 36 months in age at the time of initial clinical 
evaluation were followed longitudinally approximately every 9 months until a final 
diagnosis was determined at age 2–4 years. For analysis purposes, toddlers (median age, 27 
months) were categorized into two groups based on their final diagnosis assessment: 1) 
ASD: subjects with the diagnosis of ASD or ASD features; 2) TD: toddlers with typical 
developments. For more information see Table S1.
ADOS scores at each toddler’s final visit were used for correlation analyses with DE-ASD 
network co-expression activity scores. All but 4 toddlers were tracked and diagnosed using 
the appropriate module of the ADOS (i.e., ADOS Module-Toddler, Module-1, or Module-2) 
between the ages of 24–49 months (Table S1), an age where the diagnosis of ASD is 
relatively stable16; the remaining 4 toddlers had their final diagnostic evaluation between the 
ages of 18 to 24 months.
Blood sample collection
Blood samples were usually taken at the end of the clinical evaluation sessions. To monitor 
health status, the temperature of each toddler was monitored using an ear digital 
thermometer immediately preceding the blood draw. The blood draw was scheduled for a 
different day when the temperature was higher than 99 Fahrenheit. Moreover, blood draw 
was not taken if a toddler had some illness (e.g., cold or flu), as observed by us or stated by 
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parents. We collected four to six milliliters of blood into ethylenediaminetetraacetic-coated 
tubes from all toddlers. Blood leukocytes were captured and stabilized by LeukoLOCK 
filters (Ambion) and were immediately placed in a −20°C freezer. Total RNA was extracted 
following standard procedures and manufacturer’s instructions (Ambion).
Data processing and differential gene expression analysis of the primary dataset
The primary discovery dataset composed of 275 samples from 240 male toddlers with the 
diagnosis of ASD and TD from the general population. Gene expressions were assayed 
using Illumina HT-12 platform. All arrays were scanned with the Illumina BeadArray 
Reader and read into Illumina GenomeStudio software (version 1.1.1). Raw Illumina probe 
intensities were converted to expression values using the lumi package53. We employed a 
three-step procedure to filter for probes with reliable expression levels. First, we only 
retained probes that met the detection p-value <0.05 cut-off threshold in at least 3 samples. 
Second, we required the probes to have expression levels above 95th percentile of negative 
probes in at least 50% of samples. The probes with detection p-value >0.1 across all samples 
were selected as negative probes and their expression levels were pooled together to estimate 
the 95th percentile expression level. Third, for genes represented by multiple probes, we 
considered the probe with highest mean expression level across our dataset, after quantile 
normalization of the data. These criteria led to the selection of 14,854 protein coding genes 
as expressed in our leukocyte transcriptome data, which is similar to the previously reported 
estimate of 14,555 protein coding genes (chosen based on unique Entrez IDs) for whole 
blood by GTEx consortium54. To ensure results are not affected by the variations in the 
procedure of selecting expressed genes, we replicated all of our analyses (redoing DE 
analysis and re-constructing HC DE and XP networks) by choosing 13,032 protein coding 
genes as expressed (Fig. S13).
Quality control analysis was performed on normalized gene expression data to identify and 
remove 22 outlier samples from the dataset. Samples were marked as outlier if they showed 
low signal intensity in the microarray (average signal of two standard deviations lower than 
the overall mean), deviant pairwise correlations, deviant cumulative distributions, deviant 
multi-dimensional scaling plots, or poor hierarchical clustering, as described elsewhere18. 
After removing low quality samples, the primary dataset had 253 samples from 226 male 
toddlers including 27 technical replicates. High reproducibility was observed across 
technical replicates (mean Spearman correlation of 0.917 and median of 0.925). We 
randomly removed one of each of two technical replicates from the dataset.
The limma package55 was then applied on quantile normalized data for differential 
expression analysis in which moderated t-statistics was calculate by robust empirical Bayes 
methods56. Sample batch was used as a categorical covariate (total of two batches; both 
Illumina HT-12 platforms). Exploration graphs indicated that linear modeling of batch 
covariate was effective at removing its influence on expression values (Fig. S14). MA-plots 
of the primary dataset did not show existence of bias in the fold change estimates (Fig. S1). 
DE analysis identified 1236 differentially expressed genes with Benjamini-Hochberg FDR 
<0.05.
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Reproducibility assessment using additional microarray and RNA-Seq datasets
We performed six analyses to confirm that fold change patterns of DE genes in the primary 
dataset are robust to alterations in the analysis pipeline, are not affected by the batches, and 
are present in the vast majority of samples. First, we included additional co-variates in our 
regression models. Second, the discovery dataset (253 high quality samples from 226 male 
toddlers) is an expanded version of a dataset that we analyzed and reported in our previous 
study using a different approach1. Therefore, we compared the fold changes from non-
overlapping subjects from these two studies. Third, we performed Jack-knife resampling to 
confirm that the observed fold changes were not driven by a small subset of subjects, but 
rather shared by the vast majority of samples (Fig S1). We performed a similar analysis on 
the network activity levels and found that the higher co-transcriptional activity of DE-ASD 
networks are not driven by a small number of subjects (Fig S11). Fourth, we performed 
additional microarray transcriptome analyses to confirm that our results are replicable at 
technical and biological levels. We conducted transcriptome analysis on a second dataset 
composed of 56 randomly selected male toddlers from the primary dataset (35 ASD and 21 
TD). We also analyzed a third microarray dataset composed of 48 male toddlers with 24 
independent, non-overlapping toddlers with ASD, while 21 out of 24 TD cases overlapped 
with the primary dataset. These two datasets were assayed concurrently, but at a different 
time than the primary dataset. Moreover, in contrast to the primary dataset, the second and 
third datasets were assayed by Illumina WG-6 Chips. The pre-processing and downstream 
analysis of the second and third microarray datasets were conducted separately using the 
same approaches as the primary dataset.
Fifth, to further assess the reproducibility of the results across experimental platforms, we 
performed RNA-Seq experiments on 56 samples from an independent cohort of 12 (19 
samples) TD and 23 (37 samples) male toddlers with ASD. None of these subjects 
overlapped with those in the microarray datasets. This allowed us to ensure our results are 
not subject nor platform (i.e., microarray vs. RNA-Seq) specific. RNA-Seq libraries were 
sequenced at the UCSD IGM genomics core on a HiSeq 4000. We processed the raw RNA-
Seq data with our pipeline that starts with quality control with FastQC57. Low quality bases 
and adapters were removed using trimmomatic58. Reads were aligned to the genome using 
STAR59. STAR results were processed using Samtools60, and transcript quantification is 
done with HTseq-count61. Subsequently, low expressed genes were removed and data were 
log count per million (cpm) normalized (with prior read count of 1) using limma55. We 
performed SVA analysis62 on the normalized expression data and included the first surrogate 
variable as covariate to account for potential hidden confounding variables. Differential 
expression analysis was performed using the limma package with subjects modeled as 
random effects (Fig S4).
Finally, we explored the potential impact of variations in cell type composition1 and other 
hidden confounding variables62 on the results. As illustrated in Fig. S2, our results indicated 
that there is no statistically significant difference in the cell type composition between ASD 
and TD samples.
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ASD risk genes
ASD risk genes were extracted from the SFARI database42 on Dec. 7, 2016. We also 
included the reported risk genes from a recent meta-analysis, containing genes mutated in 
individuals with ASD but not present in Exome Aggregation Consortium database 
(ExAC)14. Together, these two resources provided 965 likely rASD genes that were used for 
the construction of the XP-ASD networks (Table S7). Previously published genes with likely 
gene damaging and synonymous mutations in siblings of subjects with ASD, who developed 
normally were retrieved from Iossifov et al.13.
ASD high confidence risk genes were extracted from the SFARI database (genes with 
confidence levels of 1 and 2), Kosmicki et al.14 (recurrent gene mutations in individuals with 
ASD, but not present in the ExAC database), Sanders et al.15, and Chang et al.7. Strong 
evidence genes with de novo protein truncating variants in subjects with ASD were extracted 
from Kosmicki et al.14 and included rASD genes that were not in the ExAC database and 
have a probability of loss-of-function intolerance (pLI) score of above 0.9. Gene names in 
these datasets were converted to Entrez IDs using DAVID tools63.
To assess the overlap of DE-ASD networks with rASD genes, we considered our list of all 
rASD genes (965 genes), different lists of high confidence rASD genes (varying in size and 
composition) and their combinations, including all SFARI rASD genes, SFARI gene levels 
1-to-3, SFARI gene levels 1 and 2, strong evidence rASD genes from Kosmicki et al.14, and 
strong evidence rASD genes from Sanders et al.15.
rASD genes with potential gene regulatory role were identified based on the gene ontology 
annotations. We considered an rASD as a potential gene regulator if it was annotated with 
either DNA-binding transcription factor activity (GO:0003700), DNA binding (GO:
0003677), or DNA-templated regulation of transcription (GO:0006355).
Construction of context specific networks
We first regressed out the interfering co-variate (i.e., batch group) from the quantile 
normalized expression values of the primary dataset (see the Data processing section). The 
Context Likelihood of Relatedness (CLR) algorithm64 was next applied on the batch 
corrected transcriptome data from ASD and TD diagnosis groups separately to construct two 
co-expression networks (technical replicates were randomly removed from the dataset prior 
to construction of the networks). The CLR algorithm employs a two-step procedure to infer 
significantly co-expressed gene pairs. First, it estimates the distribution of similarity scores 
for each gene based on the similarity that the gene shows with all other genes in the dataset 
using a mutual information metric. Second, it estimates the significance of the observed 
similarity score for each gene pair by testing how likely it is to have such a similarity score 
given the co-expression similarity score distributions of the two genes from the first step. 
The separate application of the CLR algorithm on ASD and TD samples provided global 
(i.e., all expressed genes) gene-gene co-expression similarity matrices for each diagnosis 
group. DE and expanded DE-and-rASD (XP) networks were next constructed from CLR-
derived ASD and TD similarity matrices as detailed below.
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To ensure the robustness of the results, we constructed three variants of the DE networks for 
each diagnosis group (i.e., ASD and TD; total of six networks). These networks varied in the 
number of nodes and edges, providing a tradeoff between sensitivity (number of false 
negative interactions) and specificity (number of false positive interactions) in our 
downstream analysis. Unless otherwise noted, we reported results that were reproducible in 
all three networks. The three networks include the high confidence network (HC; including 
strong evidence physical and regulatory interactions), the functional network (including 
interactions between previously known functionally related genes), and the full co-
expression network. The full co-expression network is solely based on co-expression 
patterns of DE genes (i.e., all significantly co-expressed DE gene pairs with FDR <0.05 as 
judged by the CLR algorithm). To construct the HC and functional networks, we first 
retrieved the static HC and functional networks of the detected protein-coding DE genes 
from databases. The static HC network was obtained from the Pathway Commons 
database65 and was updated to include interactions from the most recent Reactome66 and 
BioGrid67 databases. The static functional network was extracted from the GeneMania 
webserver68 and included interactions supported by co-expression, protein-protein 
interactions, genetic interactions, co-localization, shared protein domains, and other 
predictions68. The backbone, static network of all DE-ASD and DE-TD networks composed 
of at least 96% DE genes. Static HC and functional networks were made context specific by 
retaining those database-derived interactions that were significantly co-expressed in the 
diagnosis group (The static backbone networks were shared between the DE-ASD and DE-
TD networks). All figures in the main text are based on HC DE-ASD and DE-TD networks, 
and the results of functional and full co-expression networks are represented in the 
supplement.
By design, the HC network is smaller, more accurate, but potentially more biased as it 
includes genes that are more actively studied than those in the functional network. Both 
networks are smaller than the full co-expression network. Therefore, on average, the 
functional DE-ASD and DE-TD networks had 15x more interactions and 2.3x more genes 
than their HC counterparts. Similarly, the full DE-ASD and DE-TD networks had 6.4x more 
interactions and 1.05x more genes than their functional counterparts.
The XP-ASD networks were constructed using a similar approach, but from the union of 
protein-coding DE genes and 965 rASD genes. Our list of 965 rASD genes included genes 
that are ranked either as high confidence (supported with multiple studies or direct 
experimentation) or low confidence (some even have been found in healthy siblings of 
individuals with ASD). To assess the relevance of XP-ASD networks to the pathobiology of 
ASD, we also examined the association of XP-ASD networks with genes mutated in siblings 
of subjects with ASD, who developed normally. For this, we constructed two other variants 
of the XP-ASD networks by adding genes with likely gene damaging mutations (Siblings-
LGD) and Synonymous (Siblings-Syn) mutations in our list of DE and rASD genes, 
separately. We next tested if these two variants of XP-ASD networks preferentially 
incorporated mutated genes in siblings of individuals with ASD, who developed normally. 
As the sole purpose of these two network variants were to test the relevance of the main XP-
ASD network, they were not needed for follow up analyses. Similar to DE networks, the 
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main figures represent results based on the HC XP-ASD network and the results for the 
functional and full XP-ASD networks are included in the supplement.
Network and module overlap analysis
Unless otherwise noted, we used permutation tests to assess the significance of overlap 
between pairs of networks or modules. The background gene list for DE and XP networks 
were all protein coding genes that were expressed in our microarray experiments (see the 
gene expression preprocessing section for more details). DE genes did not show bias in 
terms of gene mutation rates (p-value=0.36; Wilcoxon-Mann-Whitney test) and length (p-
value: 0.45; two-sided t-test). We extracted the gene mutation rates from a previous study5.
Empirical permutation tests were conducted by 10,000 random draws from background gene 
lists and measuring the overlaps. The actual overlap was then compared to the overlap 
distribution of random draws and an empirical p-value was estimated. In cases where the 
estimated empirical p-value was zero based on 10,000 permutation tests, we performed 
90,000 additional random draws to obtain a more accurate estimation. If the estimated 
empirical p-value was still zero, a theoretical, hypergeometric-based p-value (non-zero) was 
considered. Multiple testing was corrected by the Benjamini-Hochberg procedure and FDR 
<0.1 was considered as significant, unless otherwise noted. By design, our functional and 
full DE and XP networks are highly sensitive and therefore include more than 90% of 
queried genes. Since we required replicable significant overlap of gene sets across our 
networks, this feature renders the overlap analysis robust to potential biases due to the 
network topology.
To identify genes that potentially regulate DE-ASD networks, we examined the overlap of 
DE-ASD networks with identified targets of human transcription factors as part of 
ENCODE40 and the curated Chea2016 database41. Overall, targets of 285 unique human 
transcription factors are assayed in the ENCODE and Chea2016 resources, and from these, 
20 are currently annotated as high-confidence or suggestive evidence rASD genes by the 
SFARI database (SFARI categories 1 to 3). We performed overlap analysis between targets 
of transcription factors and each of the three DE-ASD networks separately using the 
hypergeometric test through the EnrichR portal72. Some of the transcription factors were 
assayed multiple times, providing partially different sets of target genes for these 
transcription factors. For such transcription factors, we had multiple p-values from the 
overlap analysis. Therefore, we used Fisher’s method to combine the enrichment p-values 
across assays related to a given transcription factor during the analysis of each DE-ASD 
network. Next, p-values were corrected using the Benjamini-Hochberg procedure. Only 
transcription factors whose targets were significantly enriched in all three DE-ASD networks 
were considered as significantly overlapping (FDR <0.1) with the DE-ASD networks. This 
resulted in the identification of 97 unique transcription factors whose targets are 
significantly enriched in all three DE-ASD networks (Table S6). From these 97, 11 
transcription factors are currently annotated as high confidence or suggestive evidence rASD 
genes. We assessed whether rASD genes are significantly enriched among the 97 
transcription factors using a Fisher’s exact test.
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Hub analysis
The hub analysis of DE-ASD and XP-ASD networks were conducted by an integrated 
analysis of high-confidence (HC) and functional networks. By design, HC and functional 
networks each have their own advantages. Interactions in HC networks are presumably more 
accurate but potentially biased towards specific genes that are better studied. In contrast, 
hubs in functional networks are less susceptible to bias in knowledge on the interactome, but 
more prone to false positive interactions. Thus, we aimed to combine the information 
provided by the two networks to get a more accurate picture of hub genes. We first counted 
the number of interactions that each gene has in either of HC or functional networks. For the 
genes that were present in only one of the two networks, the interaction count of zero was 
considered for the other network. Then the p-value of hubness for each gene in a network 
(with the null hypothesis that the gene is not a hub) was determined by calculating the 
empirical probability of identifying a gene with the same number of interactions or higher in 
the network. Next, the hubness p-value score of each gene in HC and functional networks 
were combined together using Fisher’s method:
X2
2 = − 2 × ln pHC + ln pFunc
Where p refers to the empirical p-value of hubness for a gene in the HC and functional 
networks. X2
2
 is the chi-squared score with two degrees of freedom. The top 5% and 7% 
genes with highest X2
2
 scores were considered as hub in DE-ASD and XP-ASD networks, 
respectively.
Functional characterization of DE-ASD networks
We set two criteria to identify biological processes that are differentially expressed between 
ASD and TD diagnosis groups and are enriched in the DE-ASD networks. First, we required 
the biological process to significantly change between ASD and TD transcriptome samples 
based on GSEA69,70. Second, we required the biological process to be significantly enriched 
in the DE-ASD networks.
GSEA identified multiple gene sets that were significantly upregulated in subjects with ASD 
(FDR <0.12; Table S9), using the R version of the GSEA package and the msigdb.v5.1 
database (downloaded on Oct. 20, 2016)69,70. Significantly enriched processes in the DE-
ASD networks were identified by examining the overlap of GSEA-identified significantly 
altered gene sets with the DE-ASD networks based on empirical permutation tests, and p-
values were corrected for multiple testing using the Benjamini-Hochberg procedure. We 
excluded gene sets associated with specific reference datasets in MSigDB since their 
generalizability to our dataset has not been established (Table S9).
Biological enrichment analysis of XP-ASD networks
Significantly enriched Gene Ontology biological processes (GO-BP) were identified by 
Fisher’s exact test on terms with the 10–2000 annotated genes. The terms with Benjamini-
Hochberg estimated FDR <0.1 were deemed as significant. The enriched terms were next 
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clustered based on the GO-BP tree, extracted from the Amigo database using RamiGO 
package in R71. The general terms with more than 1000 annotated genes that spanned two or 
more clusters were removed. The list of enriched GO-BP terms and their clustering are 
provided in Table S8.
Brain developmental gene expression data
Normalized RNA-Seq transcriptome data during human neurodevelopmental time periods 
were downloaded from the BrainSpan database on Dec. 20, 201634,35. To calculate 
correlations, normalized RPKM gene expression values were log2(x+1) transformed.
Neural progenitor differentiation data
Microarray transcriptome data from the differentiation of primary human neural progenitor 
cells to neural cells43 were downloaded from the NCBI GEO database (GSE57595). The 
data were already quantile normalized and ComBat batch-corrected73. For genes with 
multiple probes, we retained the probe with the highest mean expression value.
To observe the transcriptome response of XP-ASD networks during neuron differentiation, 
we correlated the gene expression patterns with the developmental time points, considering 
the differentiation time as an ordinal variable.
human induced pluripotent stem cells (hiPSC) data
We obtained hiPSC data28 from subjects with ASD and TD controls from EMBL-EBI 
ArrayExpress (E-MTAB-6018). Gene expression counts were normalized with the TMM 
method74 and filtered to exclude low-expressed genes (genes with count per million greater 
than 1 were retained). To calculate the correlations, normalized RNA-Seq gene expression 
values were log2(x+1) transformed.
The subjects from this hiPSC study come from our center. However, none of the subjects 
overlap with those included in the transcriptome datasets in this study. Moreover, the hiPSC 
cohort includes only 8 subjects with ASD and macrocephaly, while our primary (i.e., 
discovery) leukocyte transcriptome is from 119 toddlers with ASD selected from general 
pediatric community and were not filtered based on their brain size. Moreover, the subjects 
participating in the two studies did not have the same age range and hiPSC cohort is 
composed of subjects with mean and median age of 167 and 193 months, respectively 
(toddlers in our dataset are between 12 to 48 months old; Table S1). On the sample 
collection, our transcriptome data are from leukocytes of subjects with ASD, while the 
hiPSC transcriptome is based on the reprogrammed fibroblast cells.
Regulatory effect of gene mutations on phosphorylation state of key signaling proteins
Data were extracted from a genome-wide mutational study that monitored the regulatory 
effect of gene mutations on phosphorylation status of 10 core genes of different signaling 
pathways and processes17. Genes whose mutations affected the phosphorylation status of the 
core signaling genes with FDR <0.1 were considered as the regulators of the cognate 
signaling pathway. We observed that 89 out of 316 rASD genes included in the HC DE-ASD 
network are regulators of at least one signaling pathway among RAS/ERK (as measured by 
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phosphorylation status of ERKs), PI3K/AKT (as measured by phosphorylation status of 
AKT1), and WNT/β-catenin (as measured by phosphorylation status of β-catenin) (Fisher’s 
exact test p-value <1.7 × 10−22; see Fig 5d for more details). Moreover, 34 additional genes 
were connected to the XP-ASD network only through these 89 regulator genes. Therefore, 
as our HC networks are composed of high confidence interactions, in total 39% of rASD 
genes in the HC XP-ASD network are related to these three signaling pathways in the high 
confidence XP-ASD network. In general, signaling pathways are highly inter-connected in 
the cell17. Hence, genes could affect the activity of different pathways concurrently. To 
ensure that the genes included in the XP-ASD networks are specific to the three signaling 
pathways of RAS/ERK, PI3K/AKT, and WNT/β-catenin, we reproduced the results after 
removing the genes that regulate at least two signaling genes other than ERKs, AKT1, and 
β-catenin (data not shown). To observe the specificity of these results, as negative control, 
we confirmed that the rASD genes in the XP-ASD network are not significantly enriched for 
the regulators of LAMP1 gene after excluding those genes that regulate at least two of three 
signaling pathways of RAS/ERK, PI3K/AKT, and WNT/β-catenin.
Measuring the co-expression activity of DE-ASD networks
We measured the co-expression strength of interacting genes in DE-ASD networks based on 
an unsigned Pearson’s correlation coefficient metric. To estimate the significance of the 
network activity in a set of samples, we compared the co-expression distribution of gene 
pairs in the network to a background distribution of co-expression values using the 
Wilcoxon-Mann-Whitney test in the R coin package. The network activity level was defined 
as z-transformed p-values of this comparison. Significant scores imply that at least some 
interacting gene pairs are co-expressed significantly higher than chance and hence parts of 
the network is potentially active. The background distribution was obtained by selecting 
genes with mean expression values closest to those involved in the relevant network. For 
each gene in the DE-ASD network, 10 non-overlapping genes with closest mean expression 
were selected. For example, we selected 3920 unique genes as the background for the HC 
DE-ASD network that has 392 genes. The unsigned correlations among these genes 
constituted the background distribution.
Measuring the co-expression activity of DE-ASD network during the neurodevelopmental 
period: To measure the co-expression activity of the DE-networks during brain 
neurodevelopmental periods from the BrainSpan RNA-Seq transcriptome data, we grouped 
samples from every 5 consequent time periods, starting from 8 post conception weeks and 
ending with 11 years old. The groups did not overlap in timespan.
Measuring the co-expression activity of DE-ASD network in neuron models of ASD: To 
measure DE-ASD network co-expression activity in hiPSC-derived neurons of ASD and TD 
cases, we analyzed the largest available transcriptome dataset including 8 ASD and 5 TD 
donors6. In this dataset, hiPSC-derived neural progenitor cells from each donor is 
differentiated to neurons and transcripts are measured during differentiation at 0, 2, 4, 7, and 
14 days into the differentiation. To measure the DE-ASD network activity during the 
differentiation of neural progenitors to neuronal stages, iterating 100 times, we randomly 
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selected 4 donors within each diagnosis group and measured the co-expression magnitude of 
the DE-ASD networks across the differentiation time points (n=20 samples).
Correlation of DE-ASD co-transcriptional activity with ADOS social affect scores: To map 
the co-expression activity of the DE-ASD networks on toddlers’ ADOS social affect 
(ADOS-SA) scores, we only considered ASD samples as DE-ASD networks were 
constructed based on genes that are differentially expressed between ASD and TD. toddlers 
with ASD were grouped based on a moving window on ADOS-SA scores with the width of 
4 and a step size of 1. The number of toddlers with scores of 5 and 6 were relatively few 
compared to other categories. Therefore, the first window was from ADOS-SA score 5 to 10 
(window size of 6). Moreover, to avoid biases due to number of samples in each window, the 
network activities were measured based on randomly selected sets of 20 samples from each 
window, iterating 1000 times. The correlation of ADOS-SA scores with the observed 
network activity was measured by considering the windows as ordinal values. To assess 
statistical significance, we shuffled the ADOS-SA scores of toddlers with ASD 10,000 times 
and re-calculated the network activity for each permutation (with no internal iterations).
There are some objective differences in measuring network activity during normal brain 
development versus the correlation of the leukocyte network activity with ADOS-SA scores. 
While in brain transcriptome data we hypothesized the DE-ASD networks show greater co-
expression than background, we already knew that these networks are significantly co-
expressed in toddlers with ASD and thus sought to test if their change in co-expression 
activity is dependent on ADOS-SA scores. Hence to map the relative activity of the DE-
ASD networks in leukocytes of toddlers with ASD, in a second analysis, we based the 
background co-expression on the same network in the TD toddlers (instead of random genes 
from the same samples). The distribution of co-expression scores in each ADOS-SA score 
window was compared to the co-expression distribution (Wilcoxon-Mann-Whitney test) of 
the same network after randomly selecting the same number of samples among the TD 
toddlers (n=20 ASD samples and 20 TD samples at each iteration). We repeated the 
procedure 1000 times each with a distinct ASD and TD sample combination for all three 
context-specific DE-ASD networks to get the range of the network activity at each window. 
To assess the significance of observed distribution, we performed 10,000 permutations of 
ADOS-SA scores of toddlers with ASD (with no internal iterations at each severity level).
Statistics and reproducibility
Almost all statistical analyses were conducted in the R programing environment (version 
3.5.0). For microarray data, raw Illumina probe intensities were converted to expression 
values using the lumi package53. We filtered out probes that were not expressed from the 
dataset. Through quality control assessments, we identified and removed 22 outlier samples 
from the microarray dataset. Data were next quantile normalized and differentially 
expression genes were identified using limma package55 with the experimental batch 
included as a covariate in the regression model. Genes with FDR <0.05 were deemed as 
differentially expressed. Surrogate variable analysis did not support presence of other co-
variates in the data62. Cibersort was used to examine potential impact of cell types on the 
differential expression patterns75. Technical replicates were used to assess the quality of 
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samples and then were excluded from differential expression analysis and the follow up 
analyses (e.g., co-expression network construction). RNA-Seq data were mapped and 
quantified using STAR59 and HTSeq61, respectively. Quality of RNA-Seq samples were 
examined using FastQC57. Surrogate variable analysis was performed to identify and remove 
a covariate from RNA-Seq data62. Pearson’s correlation coefficient was used for the 
comparison of fold changes across datasets. We regressed out the covariate (i.e., the 
experimental batch) before calculating the co-expression. Significantly co-expressed genes 
were identified using the CLR package in MATLAB64, and interactions with co-expression 
FDR <0.05 were considered as significant. For network co-expression activity, we used 
unsigned Pearson’s correlation coefficient to measure the co-expression magnitude of 
interactions. The co-expression magnitudes of interactions of two networks were compared 
using two-sided Wilcoxon-Mann-Whitney test. When comparing co-expression magnitudes 
in two different datasets, to ascertain that the number of samples do not influence the 
measurements, a balanced number of samples were selected randomly. In most cases we 
used permutation tests to empirically examine the significance of an observed overlap 
between two gene sets. In cases that required a large number of tests, to increase speed, we 
used either hypergeometric or fisher’s exact tests. Fisher’s exact test was used to examine 
the overlap of the constructed networks with Gene Ontology-biological process (GO-BP) 
terms. We used the RamiGO package71 to cluster significantly enriched GO-BP terms that 
are similar and overlapping in their gene content. If appropriate, all p-values were corrected 
for multiple testing. The EnrichR portal72 was used to systematically examine the 
enrichment of the DE-ASD networks for the regulatory targets of human transcription 
factors. Fisher’s method was used to combine p-values from multiple assays on the same 
transcription factor. When applicable, we specified the sample sizes (n) within the figure 
legend or table description. Non-parametric tests (e.g., Wilcoxon-Mann-Whitney and 
permutation tests) were used to avoid strong assumptions about the distribution of data in 
our statistical analyses. No statistical tests were used to predetermine sample sizes, but our 
sample sizes were larger than those reported in previous publications18,19,25. No 
randomization was performed in our cohort assignment. Data collection and analysis were 
not performed blind to the conditions of the experiments.
Reporting Summary
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Study overview.
Transcriptome analysis of 226 toddlers with ASD or typical development identified 1236 DE 
genes. We built a comprehensive “static” network of DE genes from high confidence 
physical and regulatory interactions from the Pathway Commons, BioGrid, and Reactome 
databases. To identify transcriptional programs that are active in each diagnosis group, we 
retained pairs of interacting genes in the static network that are highly co-expressed in each 
diagnosis group. This yielded context specific DE-ASD and DE-TD networks, allowing to 
compare the activity of transcriptional programs between ASD and TD conditions. To 
connect the DE-ASD network to ASD risk genes, an XP-ASD network was built using DE 
and ASD risk (rASD) genes. The DE-ASD and XP-ASD networks were analyzed in the 
context of neural differentiation, ASD neuron models, and ASD symptom severity. To 
ensure results were robust to variations in the interaction networks, we reproduced the 
results by replacing the high confidence static network (the first step in pipeline) with a 
functional and a full co-expression network (Methods).
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Fig 2. Co-expression activity is elevated in the DE-ASD network in ASD leukocytes and 
preserved in prenatal brain.
a) The DE-ASD network shows stronger co-expression in ASD toddlers compared to TD 
toddlers, suggesting pathways in the DE-ASD network are being modulated in ASD. For an 
unbiased analysis, the union of genes and interactions from DE-ASD and DE-TD networks 
was considered for this analysis (n= 119 ASD and 107 TD toddlers; see also Fig. S3). b) 
Genes in the DE-ASD network are highly expressed in the brain between 8 post conception 
weeks (pcw) to 1 year-old. For each gene, samples strongly expressing the gene (RPKM >5) 
were counted, based on BrainSpan normalized RNA-Seq data34. The background genes 
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included all protein coding genes expressed in our microarray experiment and present in 
BrainSpan (n= 187 neocortex samples; see also Fig. S5). c) The activity pattern of the DE-
ASD network across brain regions during neurodevelopment. At each time window, the 
distribution of co-expression magnitudes of interacting gene pairs in the DE-ASD network 
was measured using unsigned Pearson’s correlation coefficient (n= 121 frontal, 73 temporal, 
42 parietal, 27 occipital cortices, and 72 striatum, hippocampus, and amygdala samples 
across time points). The co-expression values were next compared to a background 
distribution using a Wilcoxon-Mann-Whitney test (Methods). The y-axis shows z-
transformed p-values of this comparison. d) Leukocyte gene co-expression in the DE-ASD 
network is conserved in the prenatal and early postnatal neocortex transcriptome. The 
Pearson’s correlation coefficient of interacting gene pairs in the DE-ASD network was 
calculated from the neocortex transcriptome (n= 187 neocortex samples; 8 pcw until 1 year-
old). The correlations were next paired with those in ASD group (n=119 subjects). A p-value 
was estimated by comparing the observed preservation of DE-ASD with that of DE-TD 
using a re-sampling method (Fig. S6). e) Overlaps of the DE-ASD network with brain 
developmental modules and networks. Modules and networks enriched for rASD genes 
significantly overlap with the DE-ASD network (FDR <0.1; permutation test). rASD 
networks: networks constructed around high confidence rASD genes7,9; rASD modules: co-
expression modules enriched for rASD genes11; other modules: modules that are not 
enriched for rASD genes11. f) Similarity of interactions of a brain co-expression network 
around rASD genes9 with ASD and TD samples as measured by Pearson’s correlation 
coefficient. Boxplots represent the similarity based on 100 random sub-samplings (n=75 
ASD and 75 TD). The x-axis represents the top percentile of positive and negative 
interactions based on the brain transcriptome interaction correlation value. Brain co-
expression is based on transcriptome data from 10–19 pcw (see also Fig S5). Boxplots 
represent the median (horizontal line), lower and upper quartile values (box), and the range 
of values (whisker), and outliers (dots).
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Fig 3. rASD genes are enriched for the regulators of the DE-ASD network.
a) Genes identified by ChIP-Seq as regulatory targets of CHD8 (CHD8-1: Sugathan et al.36; 
CHD8-2: Gompers et al.38; CHD8-3: Cotney et al.37) and FMR139, two high confidence 
rASD genes, are enriched in the DE-ASD network. Enrichment was assessed empirically 
(see also Fig. S7); dashed line shows p-value 0.05. b) The DE-ASD network significantly 
overlaps with the regulatory targets of rASD genes based on the ENCODE and Chea2016 
repositories (FDR <0.1; hypergeometric test); dashed line shows FDR 0.1. c) High 
confidence genes are significantly enriched in the XP-ASD network (hypergeometric test). 
The lists of high confidence rASD genes were extracted from SFARI database42, Kosmicki 
et al.14, Chang et al.7, and Sanders et al.15. List of likely gene damaging (LGD) and 
synonymous (Syn) mutations in siblings of ASD subjects were extracted from Iossifov et al.
13
 Dashed line indicates p-value 0.05.
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Fig 4. rASD genes potentially suppress the DE genes.
a) Interactions between DE and rASD genes are enriched for negative Pearson’s correlation 
coefficients in the ASD leukocyte transcriptome (n=119 subjects; see Fig. S7 for more 
details). b) The DE-ASD network is significantly enriched for genes that are up-regulated 
following the knock-down of CHD8 (empirical tests). Data were extracted from three 
studies: Sugathan et al.36 (CHD8 k/d_1), Gompers et al.38 (CHD8 k/d_2), and Cotney et al.
37
 (CHD8 k/d_3). See also Fig. S8. c) Expression patterns of DE-ASD genes were 
negatively correlated with rASD genes during in vitro differentiation of human primary 
neural precursor cells43 (n= 77 samples across time points; 3 fetal brain donors). In each 
panel, black circles represent the median expression of associated genes in a sample. 
Expression levels of each gene were normalized to have mean of zero and standard deviation 
of one across samples. While genes in the DE-ASD network are significantly down-
regulated during neuron differentiation (p-value = 4.4 × 10−6; Wilcoxon-Mann-Whitney 
test), XP specific genes are significantly up-regulated (p-value = 1.2×10−3; Wilcoxon-Mann-
Whitney test). The expression levels of CACNA1E, PRSS12, and CARTPT were considered 
as the markers of upper layer neurons (late stage of neural differentiation). See Fig. S7 for 
related details.
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Fig 5. The architecture of the XP-ASD network implicates PI3K/AKT, RAS/ERK, WNT/β-
catenin pathways as core dysregulated processes in ASD, regulated by rASD genes.
a) Summary of enriched biological processes in the XP-ASD network. Each node represents 
a biological process that is significantly enriched in the XP-ASD network (two-sided 
Fisher’s exact test). Nodes that preferentially include rASD and DE genes are represented by 
purple and green colors, respectively. The interactions among terms represent the connection 
patterns of their cognate genes in the XP-ASD network with thicker interactions indicating 
more significant connections (hypergeometric test). Only connections with p-value <0.05 are 
shown. This illustration covers 86% of genes involved in the XP-ASD network. b) 
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Significantly enriched processes in the DE-ASD network (Benjamini-Hochberg corrected 
FDR <0.1; hypergeometric test). These processes are also up-regulated in ASD leukocytes 
based on GSEA (n=119 ASD and 107 TD). c) The connected graph of hubs in the XP-ASD 
network. Green nodes represent hub genes in both XP-ASD and DE-ASD networks, while 
XP-ASD network-only hub genes are in purple. See Fig. S9 for the network with all gene 
labels. d) Significant enrichment of rASD genes in the XP-ASD network for the regulators 
of RAS/ERK, PI3K/AKT, WNT/β-catenin pathways. The x-axis indicates the p-value that 
gene mutations would dysregulate the corresponding signaling pathways. The background is 
composed of all genes that were assayed in Brockmann et al.47, excluding rASD and DE 
genes. The significance of enrichment of rASD genes in XP-ASD network for the regulators 
of signaling pathways were examined using Wilcoxon-Mann-Whitney test with background 
genes (illustrated in black) as control.
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Fig 6. The DE-ASD network show increased gene co-expression in differentiating neurons of 
ASD.
a) The genes in the DE-ASD network are highly expressed during neural differentiation of 
hiPSCs from ASD and TD cases48 (p-value 7.4 × 10−25; two-sided Wilcoxon-Mann-
Whitney test). For each gene, its median normalized expression at neural progenitor and 
neuron stages was considered (n= 65 hiPSC-derived neural progenitor and neuron samples 
from 13 donors). Similar patterns were observed when analyzing each stage independently. 
b) The DE-ASD network shows higher expression level in hiPSC-derived neural progenitor 
and neuron stages of individuals with ASD. Expression data for each gene was normalized 
to have mean zero and variance of one. Boxplots represent the distribution of median 
expression levels genes involved in the DE-ASD network at each differentiation time point. 
A mixed linear regression with subjects as random effects was used to estimate the 
significance of the observed pattern (n=65 samples from 13 donors across 5 time points). 
This demonstrated the diagnosis group as a significant factor in expression level of genes 
involved in the DE-ASD network (p-value: 0.018; estimate: 0.31; std. err.: 0.13; t-statistics: 
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2.36; df: 57). c) The DE-ASD network shows higher co-expression activity in ASD derived 
neural progenitors and neurons. To estimate the co-expression strength of interacting gene 
pairs in DE-ASD network in neural progenitor and neurons of in each diagnosis group, 
iterating 100 times, we randomly selected 4 individuals from a diagnosis group and 
measured the co-expression strength of the DE-ASD network at neural progenitor 
differentiation time points of day 0, 2, 4, 7, and 14 (n=20 samples). The boxplots represent 
the distribution of z-transformed p-values of co-expression strength as measured by a two-
sided Wilcoxon-Mann-Whitney test. d)The highest co-expression activity of the DE-ASD 
network in subjects with ASD coincides with the proliferation period (Day 0-to-4) of neural 
progenitors, and then its transcriptional activity gradually decreases. See Fig. S10 for more 
details. Boxplots represent the median (horizontal line), lower and upper quartile values 
(box), and the range of values (whisker), and outliers (dots).
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Fig 7. Co-expression magnitude of the DE-ASD network correlates with ASD severity.
a) ASD toddlers were sorted by their ADOS social affect scores (ADOS-SA) with higher 
scores representing more severe cases. The network activity was measured in a running 
window on ADOS-SA scores. The overall activity of the DE-ASD network in a set of 
samples was measured by comparing the co-expression magnitude of interactions in the 
network with the background derived from the same set of samples (Methods). To ensure 
robustness of the results, we measured the co-expression activity of the DE-ASD network at 
each severity group by randomly selecting n=20 subjects with ASD from that severity level, 
iterating 1000 times. The left inset panel illustrates the distribution of observed correlation 
values of DE-ASD network with the ADOS-SA severity, and compares it with permuted 
data from10,000 random shuffling of ADOS-SA scores of subjects with ASD (two-sided p-
value <10−6; permutation test; see Fig. S11). b) The relative co-expression magnitude of the 
DE-ASD networks compared to TD cases. The relative activity level was estimated by 
comparing the co-expression strength of interactions in the DE-ASD network between ASD 
and TD toddlers. For each severity group, n=20 ASD samples in that ADOS-SA range were 
randomly selected and compared to n=20 random TD samples, iterating 1000 times. 
Significance of the trend was evaluated by 10,000 permutations of the ADOS-SA scores in 
toddlers with ASD (two-sided p-value <10−6; permutation test; see Fig. S11–S12). Boxplots 
represent the median (horizontal line), lower and upper quartile values (box), and the range 
of values (whisker), and outliers (dots).
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